1. Home
  2. JCE vs INBX Comparison

JCE vs INBX Comparison

Compare JCE & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JCE
  • INBX
  • Stock Information
  • Founded
  • JCE 2007
  • INBX 2010
  • Country
  • JCE United States
  • INBX United States
  • Employees
  • JCE N/A
  • INBX N/A
  • Industry
  • JCE Trusts Except Educational Religious and Charitable
  • INBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • JCE Finance
  • INBX Health Care
  • Exchange
  • JCE Nasdaq
  • INBX Nasdaq
  • Market Cap
  • JCE 244.6M
  • INBX 237.5M
  • IPO Year
  • JCE N/A
  • INBX 2020
  • Fundamental
  • Price
  • JCE $15.26
  • INBX $15.83
  • Analyst Decision
  • JCE
  • INBX Hold
  • Analyst Count
  • JCE 0
  • INBX 1
  • Target Price
  • JCE N/A
  • INBX N/A
  • AVG Volume (30 Days)
  • JCE 49.7K
  • INBX 118.1K
  • Earning Date
  • JCE 01-01-0001
  • INBX 08-13-2024
  • Dividend Yield
  • JCE 9.26%
  • INBX N/A
  • EPS Growth
  • JCE N/A
  • INBX N/A
  • EPS
  • JCE N/A
  • INBX 118.83
  • Revenue
  • JCE N/A
  • INBX $1,687,000.00
  • Revenue This Year
  • JCE N/A
  • INBX N/A
  • Revenue Next Year
  • JCE N/A
  • INBX N/A
  • P/E Ratio
  • JCE N/A
  • INBX $0.13
  • Revenue Growth
  • JCE N/A
  • INBX 24.26
  • 52 Week Low
  • JCE $11.64
  • INBX $10.80
  • 52 Week High
  • JCE $14.28
  • INBX $18.95
  • Technical
  • Relative Strength Index (RSI)
  • JCE 54.30
  • INBX 55.90
  • Support Level
  • JCE $15.04
  • INBX $14.67
  • Resistance Level
  • JCE $15.28
  • INBX $16.35
  • Average True Range (ATR)
  • JCE 0.17
  • INBX 0.65
  • MACD
  • JCE -0.01
  • INBX -0.09
  • Stochastic Oscillator
  • JCE 55.00
  • INBX 45.59

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities (the Options Strategy).

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: